Novel oral anti-influenza prodrug candidate AV5075S.
暂无分享,去创建一个
Y. Ivanenkov | M. Veselov | V. Bichko | N. Shevkun | R. Karapetian | P. Yamanushkin | I. Fedyakina | A. Ivachtchenko | I. Leneva | O. Mitkin | Olga V Mokrushina | Olga O Nevolina
[1] Y. Ivanenkov,et al. A novel influenza virus neuraminidase inhibitor AV5027. , 2013, Antiviral research.
[2] Jinn-Moon Yang,et al. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. , 2013, Organic & biomolecular chemistry.
[3] T. Rungrotmongkol,et al. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. , 2012, Journal of molecular graphics & modelling.
[4] Ravi P. Shah,et al. ICH guidance in practice: degradation behaviour of oseltamivir phosphate under stress conditions. , 2012, Journal of pharmaceutical and biomedical analysis.
[5] George F. Gao,et al. Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition , 2011, PLoS pathogens.
[6] M. Yamashita,et al. Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza , 2010, Antiviral chemistry & chemotherapy.
[7] Ming-Rong Zhang,et al. Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802. , 2008, Bioorganic & medicinal chemistry letters.
[8] Yasuyoshi Watanabe,et al. A method for the synthesis of an oseltamivir PET tracer. , 2008, Bioorganic & medicinal chemistry letters.
[9] K. Albert,et al. Chemical stability of oseltamivir in oral solutions. , 2007, Die Pharmazie.
[10] L. Di,et al. Development and application of high throughput plasma stability assay for drug discovery. , 2005, International journal of pharmaceutics.
[11] R Abagyan,et al. High-throughput docking for lead generation. , 2001, Current opinion in chemical biology.
[12] R. Webster,et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.
[13] W. Lew,et al. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[14] T. Ebner,et al. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[15] R. Grunert,et al. THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES. , 1965, Virology.
[16] Lloyd H. Michael,et al. The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.
[17] M. Griffin. Influenza vaccination: a 21st century dilemma. , 2013, South Dakota medicine : the journal of the South Dakota State Medical Association.
[18] S. Rathore,et al. Synthesis, Isolation and Characterization of Process-Related Impurities in Oseltamivir Phosphate , 2012 .
[19] S. Kailasam. Rapid method development to study plasma stability of diverse pharmaceutical compounds using Rapid Resolution LC and triple quadrupole MS , 2009 .
[20] T. Foderaro,et al. Research and Development of a Second-Generation Process for Oseltamivir Phosphate, Prodrug for a Neuraminidase Inhibitor , 2004 .
[21] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..